Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease
NCT ID: NCT06778447
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
496 participants
INTERVENTIONAL
2025-02-17
2028-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a randomized, sham-controlled, multi-center, double-blind clinical trial with an open label roll-in period of one participant per site in which participants with lumbar discogenic pain associated with DDD will receive one VIA Disc NP treatment to each affected level (up to 2 levels). Participants enrolled after the roll-in stage will be randomized on a 2:1 basis to receive either a single VIA Disc NP intradiscal injection at 1 or 2 levels or the sham procedure at 1 or 2 levels. At 12 months, participants in the sham arm with continued symptoms may cross-over, receive VIA Disc NP, and will restart the study visit schedule, completing an additional 12 months of follow-up post-cross-over.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs
NCT05201287
VIA Disc Nucleus Pulposus Older Patients Pilot
NCT05412277
ASCEND: A Clinical Trial to Evaluate the Safety and Effectiveness of VIA Disc NP, a Supplement for Degenerated Intervertebral Discs
NCT06615505
EvaluatIon of Autologous Nucleus Pulposus Cells (aNPC) in Degenerative Disc Disease
NCT07168603
Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain
NCT03709901
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VIA Disc NP
A single dose, intradiscal delivery of 100mg of VIA Disc NP mixed with sterile saline according to product Instructions for Use (IFU) and administered at up to two affected levels, L1-S1.
VIA Disc NP
VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Sham
The procedure will be identical to the investigational procedure with the following exception: A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
Sham
A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VIA Disc NP
VIA Disc NP is processed from donated cadaveric disc tissue, lyophilized, and micronized to particles.
Sham
A 20G spinal needle will be carefully inserted through the skin and muscle of the back but WILL NOT penetrate the annulus fibrosus of the intervertebral disc. No saline or VIA Disc NP will be injected.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of moderate to severe DDD on MRI, Modified Pfirrmann Grade 3-7
* Chronic axial midline low-back pain in the absence of lower extremity motor/sensory/reflex changes with or without referred non-radicular leg pain for at least 6 months prior to screening; unresponsive to at least 3 months of conservative care
* Low-back pain severity score of ≥ 40 to ≤ 90 mm on the VAS
* ODI score of ≥ 40 to ≤ 80
* Positive sustained hip flexion test
* Demonstrated intolerance to sitting
* Able to give voluntary, written informed consent to participate and have signed an Informed Consent Form specific to this study
* Willing and able to comply with all study procedures and availability for the duration of the study with a life expectancy of \> 2 years
Exclusion Criteria
* Involvement of more than two lumbar discs as evidenced by 3 or more discs with Modified Pfirrmann grade of 3 or greater
* Disc height of less than 4mm for any disc between L1-S1
* Symptomatic vertebral compression fracture
* Previous surgical treatment of the lumbar spine
* History of sacroiliac (SI) joint fusion within the past six months
* Received lumbar epidural or intradiscal steroid injection, lumbar facet joint steroid injection, lumbar radiofrequency ablation, provocative or anesthetic discography, SI joint pain injection, injection of methylene blue, dextrose, glucosamine, and chondroitin sulfate, or biacuplasty within 3 months of the Day 0 procedure
* Received intraosseous radiofrequency nerve ablation procedure at the same or adjacent level (e.g., Basivertebral nerve ablation or sinuvertebral nerve ablations)
* Received prior intradiscal stem cell/progenitor cell therapy or other biological intervention (e.g., MSC, PRP) at the target level within 12 months of the Day 0 procedure
* Evidence of dynamic instability on lumbar flexion-extension radiographs (\>3 mm)
* Grade 2 or higher spondylolisthesis at the target level, lumbar spondylitis or other undifferentiated spondyloarthropathy, or Type III Modic changes adjacent to the target disc
* Radiographic evidence of a full thickness annular tear at the target disc or other abnormal disc morphology
* Clinical suspicion of facet pain as primary pain generator
* A systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, recent history of myocardial infarction, uncontrolled diabetes (\>7.0% HbA1C), etc.)
* Received VIA Disc NP previously.
* Deemed unsuitable for clinical study participation by the Investigator
* Evidence of substance abuse (including marijuana); note: subjects using prescribed extended-release narcotics (e.g., fentanyl patch, MS Contin, oxycontin) within the 3 months prior to screening and subjects on long-acting opioids may be given option to wean off opiates before enrollment; subjects on short-acting opiates (e.g., hydrocodone, oxycodone, tramadol, etc.) may be included and utilization monitored after the treatment
* Opioid use of more than 90 MME/day
* Currently receiving treatment with radiation, chemotherapy, immunosuppression, or chronic steroid therapy (prednisone, or its equivalent, use of up to 5 mg/qd, or inhalation steroids for asthma is allowed)
* Metal or ceramic implants in the lumbar spine region
* Contraindications to MRI, including non-MRI compatible devices and active implantable devices such as spinal cord stimulators, intrathecal pumps, etc.
* Involved in ongoing or closed (within 6 months of screening visit) litigation related to their back pain condition
* Any mental instability, unstable bipolar disorders, unmanaged post-traumatic stress disorder (PTSD) or uncontrolled anxiety/depression and/or require new or changed anti-depressants or anti-psychotic medications within 3 months of enrollment
* Diagnosis of any traumatic neurological disorders that may impact the study as per the judgement of the Investigator
* Women who are pregnant or breastfeeding at the time of enrollment and/or plan to become pregnant during the study; pregnancy is confirmed by:
* a positive pregnancy test during the screening visit
* self-reported pregnancy
* Women of childbearing potential (WOCBP) who are not using a reliable form of contraception (as determined by the Investigator)
* Received any experimental drug or device to treat the same condition used within 6 months prior to the screening visit or during the course of the clinical trial
* Other persistent pain/nerve issues including, for example, radiculopathy, leg pain, cauda equine syndrome, etc.
22 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
VIVEX Biologics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Interventional Pain Management Napa Valley Orthopedic Medical Group
Napa, California, United States
Source Healthcare
Santa Monica, California, United States
Premier Spine and Pain Institute
Thornton, Colorado, United States
The Orthopaedic Institute
Gainesville, Florida, United States
Georgia Pain Management
Woodstock, Georgia, United States
Henry Community Health
New Castle, Indiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Spine Institute of Louisiana
Shreveport, Louisiana, United States
Paradigm Health System
Slidell, Louisiana, United States
Nevada Advanced Pain Specialists
Reno, Nevada, United States
Premier Pain Centers
Shrewsbury, New Jersey, United States
Crystal Coast Pain Management
New Bern, North Carolina, United States
Pacific Sports & Spine
Eugene, Oregon, United States
Pain Specialists of America
Killeen, Texas, United States
Procura Pain & Spine
Shenandoah, Texas, United States
Precision Spine Care
Tyler, Texas, United States
The Spine and Nerve Center C/O Clinical Research
Charleston, West Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Gabriel Wirnowski
Role: primary
Dennis Dickman
Role: primary
Tina Hall
Role: primary
Rebecca Layman
Role: primary
Krista Kachnik
Role: primary
Chris Myers
Role: primary
Madeline Benson
Role: primary
Kathryn Gee
Role: primary
Amy Harum
Role: primary
Katie Fabian
Role: primary
Angela Ballew
Role: primary
Courtney Harvey
Role: primary
Jessica Youngblood
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VIA-2024-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.